Lower Serum Triiodothyronine Levels Constitute an Independent Risk Factor for Dyslipidemia in Levothyroxin-Treated Patients
Main finding · Incident dyslipidemiaResult — go to the resultAdjusted odds ratio 3.558 95% CI 1.173–12.045Authors' conclusion
Low FT3 levels in LT4-treated patients represent an independent risk factor for dyslipidemia, even with normal TSH levels. This challenges the adequacy of TSH-centric management and supports the need for therapeutic strategies that ensure T3 homeostasis to mitigate dyslipidemia and cardiovascular risk.
Study context
- Population
- Participants of ELSA-Brasil (civil servants aged 35–74) who developed hypothyroidism, initiated levothyroxine (LT4) and achieved TSH normalization; preexisting dyslipidemia excludedLT4-treated, TSH normalized
- Participants
- 105 participants
- Exposure
- Free T3 (FT3) ≤0.28 ng/dL vs >0.28 ng/dL in LT4-treated patients
- Outcome
- Incidence of dyslipidemia (non-HDL cholesterol ≥160 mg/dL or statin use)
Methodological detailsELSA-Brasil cohort, 3 study waves (2008-2019), multivariable logistic regression
- ELSA-Brasil cohort
- 3 study waves (2008-2019)
- Multivariable logistic regression
Main finding
Incident dyslipidemia
Adjusted odds ratio
3.558
95% CI 1.173–12.045
P = 0.031
By group
FT3 ≤0.28 ng/dLvs FT3 >0.28 ng/dL
aOR 3.558 (95% CI 1.173–12.045); P = 0.031
As reported in the abstract
Observational data: associations, not effects.
Original publication
Lower Serum Triiodothyronine Levels Constitute an Independent Risk Factor for Dyslipidemia in Levothyroxin-Treated Patients. Endocr Pract. Published 5 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →